# Risk factors and immune landscape of early local tumor progression after microwave ablation for lung cancer: a retrospective nested case-control study

**Authors:** Nan Wang, Jingwen Xu, Ji Ma, Siyi Niu, Xiuhong Ren, Qi Xie, Zhigang Wei, Xin Ye

PMC · DOI: 10.3389/fimmu.2026.1767345 · Frontiers in Immunology · 2026-03-06

## TL;DR

This study identifies risk factors and immune changes linked to early tumor regrowth after microwave ablation for lung cancer.

## Contribution

The study provides new insights into risk factors and immune alterations associated with early local tumor progression after microwave ablation.

## Key findings

- Large tumor size, proximity to the pulmonary hilum, and insufficient ablative safety margin are key risk factors for early LTP.
- Early LTP is associated with reduced CD4+ T cells and IL-2, and elevated IL-10 and IL-6 levels at one-month post-MWA.
- Immune parameter changes were observed in peripheral blood one month after microwave ablation.

## Abstract

Microwave ablation (MWA) is an effective therapy for early-stage inoperable non-small cell lung cancer (NSCLC), yet its efficacy is limited by early local tumor progression (LTP). As early LTP is often suggestive of incomplete ablation, this study aimed to identify its risk factors and to characterize the associated changes in systemic immune parameters.

This single-center retrospective nested case-control study enrolled patients with NSCLC who underwent MWA between January 1, 2021, and December 31, 2023. Patients were divided into an early LTP group (LTP ≤6 months post-MWA) and a control group. Clinical data and peripheral blood immune parameters at pre-MWA, one-week post-MWA, and one-month post-MWA were collected. Univariate and multivariate logistic regression analyses were used to identify independent risk factors and dynamic changes in immune indicators compared between groups.

A total of 76 patients were included (19, early LTP group; 57, control group). Multivariate analysis identified three independent risk factors for early LTP: maximum tumor diameter >30 mm (OR = 2.681, 95%CI: 1.218–5.901, P = 0.014), distance to hilum ≤10 mm (OR = 3.280, 95%CI: 1.678–6.411, P = 0.001), and ablative safety margin (≤5.0 mm) (OR = 4.152, 95%CI: 1.922–8.968, P < 0.001). Comparative analysis of peripheral blood immune parameters revealed distinct patterns between groups at one-month post-MWA. Compared to the control group, the early LTP group exhibited a significant reduction in CD4+ T cells (P = 0.040) and IL-2 levels (P = 0.020), whereas IL-10 (P < 0.001) and IL-6 (P = 0.004) levels were significantly elevated.

Large tumor size, proximity to the pulmonary hilum, and an insufficient ablative safety margin are key risk factors for early LTP post-MWA. The development of early LTP is associated with significant alterations in specific peripheral blood immune cell subsets and cytokine levels at one-month post-MWA.

## Linked entities

- **Diseases:** non-small cell lung cancer (MONDO:0005233), lung cancer (MONDO:0005138)

## Full-text entities

- **Genes:** IL2 (interleukin 2) [NCBI Gene 3558] {aka IL-2, TCGF, lymphokine}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}
- **Diseases:** NSCLC (MESH:D002289), lung cancer (MESH:D008175), tumor (MESH:D009369)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13002626/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13002626/full.md

## References

40 references — full list in the complete paper: https://tomesphere.com/paper/PMC13002626/full.md

---
Source: https://tomesphere.com/paper/PMC13002626